Innoviva, Inc. 8-K
PositiveEarningsNew guidance
Armata share-price gains drove the profit surge; newly approved NUZOLVENCE is slated for H2 2026 commercialization.
Filed 2026-02-25 16:57 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q4 and FY2025 results with 2026 sales outlook. Total revenue grew 25% in Q4 and 15% for FY2025; net income also rose sharply, primarily on favorable investment fair-value changes. Innoviva expects 2026 IST U.S. net product sales of $150M or more and plans to commercialize newly approved NUZOLVENCE in H2 2026, with a partner or independently.
Key Figures
| Metric | Q4 2025 | Q4 2024 | Y/Y |
|---|---|---|---|
| Total revenue | $114.6M | $91.8M | 25% |
| Royalty revenue, net | $54.9M | $62.5M | -12.2% |
| Net product sales | $59.1M | $28.9M | 104% |
| Income from operations | $39.0M | $43.1M | -9.62% |
| Net income | $164.2M | $20.3M | 707% |
| Diluted EPS | $1.94 | $0.26 | 646% |
| Metric | FY2025 | FY2024 | Y/Y |
|---|---|---|---|
| Total revenue | $411.3M | $358.7M | 15% |
| Royalty revenue, net | $236.5M | $241.7M | -2.17% |
| Net product sales | $172.1M | $97.5M | 77% |
| Income from operations | $163.7M | $166.9M | -1.87% |
| Net income | $271.2M | $23.4M | 1,060% |
| Diluted EPS | $3.30 | $0.36 | 817% |
- Q4 and FY2025 favorable changes in fair values of equity and long-term investments totaled $153.8M and $161.6M, respectively, primarily from Armata share-price appreciation. The changes helped drive net income, while operating income declined amid increased research and development investment.
- FY2025 operating cash flow was $196.9M, up from $188.7M. Cash and cash equivalents were $550.9M at year-end; royalty and product-sale receivables were $93.3M.
- IST U.S. net product sales were $119.2M for FY2025, up 47%. The $125M share repurchase program began in Q4; 797,298 shares had been repurchased for $16.0M since inception.
Guidance
- 2026 IST U.S. net product sales: $150M or more.
Investor Takeaways
- Track 2026 IST U.S. net product sales against the $150M-or-more outlook.
- NUZOLVENCE commercialization is planned for H2 2026; watch whether Innoviva proceeds with a partner or independently.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3